切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2021, Vol. 15 ›› Issue (02) : 90 -98. doi: 10.3877/cma.j.issn.1674-0807.2021.02.005

所属专题: 文献

论著

成纤维细胞生长因子受体1与乳腺癌临床病理特征相关性的Meta分析
李娜1, 梁栋1,(), 王秋丽1, 杨秦蘅1, 闫园1   
  1. 1. 450003 郑州,河南大学河南省人民医院乳腺外科
  • 收稿日期:2020-11-16 出版日期:2021-04-01
  • 通信作者: 梁栋

Correlation between fibroblast growth factor receptor 1 and clinicopathological characteristics of breast cancer: a meta-analysis

Na Li1, Dong Liang1,(), Qiuli Wang1, Qinheng Yang1, Yuan Yan1   

  1. 1. Department of Breast Surgery, Henan Provincial People’s Hospital, Henan University, Zhengzhou 450003, China
  • Received:2020-11-16 Published:2021-04-01
  • Corresponding author: Dong Liang
引用本文:

李娜, 梁栋, 王秋丽, 杨秦蘅, 闫园. 成纤维细胞生长因子受体1与乳腺癌临床病理特征相关性的Meta分析[J/OL]. 中华乳腺病杂志(电子版), 2021, 15(02): 90-98.

Na Li, Dong Liang, Qiuli Wang, Qinheng Yang, Yuan Yan. Correlation between fibroblast growth factor receptor 1 and clinicopathological characteristics of breast cancer: a meta-analysis[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(02): 90-98.

目的

探讨成纤维细胞生长因子受体1(FGFR1)表达与乳腺癌临床病理特征间的相关性。

方法

检索中国知网(CNKI)、万方医学网、中国生物医学文献(SinoMed)、PubMed、外文医学信息资源检索平台(FMRS)上关于FGFR1表达与乳腺癌临床病理特征相关性的研究,据纳入与排除标准进行文献筛选和数据提取,用Newcastle-Ottawa Scale(NOS)量表对所纳入文献进行质量评价。采用Stata 16.0软件对数据进行Meta分析,评估FGFR1阳性表达率与乳腺癌临床病理特征间的相关性。

结果

共纳入12项研究,共4 188例患者。淋巴结转移乳腺癌患者FGFR1阳性表达率高于没有淋巴结转移的患者(OR=1.56,95%CI: 1.19~2.04,P=0.001)。TNM分期Ⅲ、Ⅳ期乳腺癌患者FGFR1阳性表达率高于Ⅰ、Ⅱ期患者(OR=1.86,95%CI:1.08~3.21,P =0.025)。ER阳性乳腺癌患者FGFR1阳性表达率高于ER阴性患者(OR=1.74,95%CI:1.39~2.19,P<0.001)。FGFR1阳性表达率在PR阳性与PR阴性、HER-2阳性与HER-2阴性、组织学3级与组织学1、2级乳腺癌患者之间比较,差异均无统计学意义(OR=0.84,95%CI:0.62~1.13,P=0.251;OR=0.98,95%CI:0.51~1.90,P=0.955;OR=1.67,95%CI:0.95~2.93,P=0.073)。

结论

FGFR1与多项乳腺癌临床病理特征有相关性,可能成为乳腺癌不良预后的指标和治疗靶点。

Objective

To investigate the correlation between the expression of fibroblast growth factor receptor 1 (FGFR1) and the clinicopathological characteristics of breast cancer.

Methods

The databases including the China National Knowledge Base (CNKI), Wanfang Med Online, Chinese Biomedical Literature (SinoMed), PubMed and Foreign Medical Literature Retrieval Service (FMRS) were searched for the studies on the correlation between FGFR1 expression and clinical pathological characteristics of breast cancer. According to the inclusion and exclusion criteria, literature screening and data extraction were performed, and the quality of the included literature was evaluated using the Newcastle-Ottawa Scale (NOS). A meta-analysis was performed using the Stata 16.0 software to explore the correlation between positive expression rate of FGFR1 and clinicopathological characteristics of breast cancer.

Results

A total of 12 studies were eligible, including 4 188 patients. The positive expression rate of FGFR1 in breast cancer patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (OR=1.56, 95%CI: 1.19-2.04, P=0.001). The positive expression rate of FGFR1 in TNM stage Ⅲ and Ⅳ breast cancer patients was significantly higher than that in TNM stage Ⅰ and Ⅱ breast cancer patients (OR=1.86, 95%CI: 1.08-3.21, P=0.025). The positive expression rate of FGFR1 in ER-positive breast cancer was significantly higher than that of ER-negative breast cancer (OR=1.74, 95%CI: 1.39-2.19, P<0.001). The positive expression rate of FGFR1 showed no significant difference between PR positive and PR negative, HER-2 positive and HER-2 negative, histological grade 3 and grade 1-2 breast cancer (OR=0.84, 95%CI: 0.62-1.13, P=0.251; OR=0.98, 95%CI: 0.51-1.90, P=0.955; OR=1.67, 95%CI: 0.95-2.93, P=0.073).

Conclusion

FGFR1 is correlated with several clinicopathological characteristics of breast cancer and can be used as an indicator of poor prognosis and treatment target of breast cancer.

表1 Newcastle-Ottawa Scale文献质量评价量表
图1 文献筛选流程图
表2 纳入文献特征及质量评价
图2 淋巴结转移与未转移乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图3 淋巴结转移与未转移乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
图4 TNM分期Ⅲ、Ⅳ期与Ⅰ、Ⅱ期乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图5 TNM分期Ⅲ、Ⅳ期与Ⅰ、Ⅱ期乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
图6 ER阳性与ER阴性乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图7 ER阳性与ER阴性乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
图8 PR阳性与PR阴性乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图9 PR阳性与PR阴性乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
图10 HER-2阳性与HER-2阴性乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图11 HER-2阳性与HER-2阴性乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
图12 组织学分级3级与组织学分级1、2级乳腺癌患者癌组织中FGFR1阳性表达率比较森林图
图13 组织学分级3级与组织学分级1、2级乳腺癌患者癌组织中FGFR1阳性表达率比较漏斗图
[1]
Gru AA, Allred DC. FGFR1 amplification and the progression of non-invasive to invasive breast cancer[J]. Breast Cancer Res, 2012,14(6):116.
[2]
林明臻,王阳,杨福乾,等. FGFR1在乳腺癌组织中的表达及意义[J]. 潍坊医学院学报,2019,41(4):292-294.
[3]
Nedeljkovic′ M, Tanic′ N, Dramic′anin T, et al. Importance of copy number alterations of FGFR1 and C-MYC genes in triple negative breast cancer[J]. J Med Biochem, 2019,38(1):63-70.
[4]
Wells GA, Shea BJ, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [J]. Appl Eng Agric, 2012, 18(6):727-734.
[5]
李幼平.循证医学[M].北京:人民卫生出版社,2014:115-120.
[6]
Jacquemier J, Adelaide J, Parc P, et al. Expression of the FGFR1 gene in human breast-carcinoma cells [J]. Int J Cancer, 1994, 59(3):373-378.
[7]
Elbauomy ES, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis[J]. Breast Cancer Res, 2007,9(2):R23.
[8]
Tiburcio M, Costa SM, DE Fatima DM, et al. Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance[J]. Oncol Lett, 2012,4(4):647-657.
[9]
Jang M, Kim E, Choi Y, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma[J]. Breast Cancer Res, 2012,14(4):R115.
[10]
张炎. FGFRI在乳腺癌组织中的表达及意义的研究[D]. 河北医科大学,2012.
[11]
李庆霞,颜聪亚,闫晓路,等. 乳腺浸润性导管癌组织FGFR1和Survivin表达临床意义分析[J]. 中华肿瘤防治杂志,2013, 20(17):1315-1318.
[12]
任冬飞. FGFR1,AIB1在乳腺浸润性导管癌中的表达及相关性研究[D]. 石家庄:河北医科大学,2014.
[13]
李星,刘延锦,韩娜,等. 成纤维细胞生长因子受体1和细胞核增殖抗原在乳腺癌组织中的表达及其相关性[J]. 中华实验外科杂志,2015,32(5):998-1000.
[14]
Cheng CL, Thike AA, Tan SY, et al. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2015,151(1):99-111.
[15]
Shi YJ, Tsang JY, Ni YB, et al. FGFR1 is an adverse outcome indicator for luminal A breast cancers[J]. Oncotarget, 2016, 7(4):5063-5073.
[16]
Wu J, Wang Y, Liu J, et al. Effects of FGFR1 gene polymorphisms on the risk of breast cancer and FGFR1 protein expression[J]. Cell Physiol Biochem, 2018, 47(6):2569-2578.
[17]
王宇航,宋全福,吴俊强,等. ER阳性乳腺癌中FGFR1蛋白的表达与ER及预后的关系[J]. 中国癌症杂志,2019,29(05):345-351.
[18]
张丽霞,李庆霞. 成纤维生长因子受体1在乳腺癌中的研究进展[J]. 医学研究生学报,2014,27(8):884-887.
[19]
Drago JZ, Formisano L, Juric D, et al. FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR+) breast cancer[J]. Clin Cancer Res, 2019,25(21):6443-6451.
[20]
Wellberg EA, Kabos P, Gillen AE, et al. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation[J]. JCI Insight, 2018,3(14):e120594.
[21]
Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer[J]. Cancer Res, 2010,70(5):2085-2094.
[22]
张丽霞. Luminal型乳腺癌FGFR1、Ki67的表达及内分泌耐药相关性研究[D]. 河北医科大学,2015.
[23]
Chae YK, Hong F, Vaklavas C, et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH trial (EAY131) subprotocol W[J]. J Clin Oncol,2020,38(21):2407-2417.
[24]
Massabeau C, Sigal-Zafrani B, Belin L, et al. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?[J]. Breast Cancer Res Treat, 2012,134(1):259-266.
[25]
Sahores A, May M, Sequeira GR, et al. Targeting FGFR with BGJ398 in breast cancer: effect on tumor growth and metastasis[J]. Curr Cancer Drug Targets, 2018,18(10):979-987.
[26]
Ye T, Wei X, Yin T, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis[J]. Breast Cancer Res Treat, 2014,143(3):435-446.
[27]
Kang J, Choi YJ, Seo BY, et al. A selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment[J]. Sci Rep, 2019,9(1):8726.
[28]
Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy[J]. Breast Cancer Res, 2017,19(1):18.
[29]
André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer[J]. Clin Cancer Res, 2013,19(13):3693-3702.
[30]
Shao W, Li S, Li L, et al. Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun[J]. Protein Cell,2019,10(3):161-177.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[15] 王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
阅读次数
全文


摘要